## PODD: Insulet Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%); PEG 2.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($268.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Braun Stacey Associates Inc. Makes New Investment in Insulet Corporation $PODD**
- Source: MarketBeat | 20260103T010923 | Bullish | Relevance: 97%
- Braun Stacey Associates Inc. recently made a new investment in Insulet Corporation (NASDAQ: PODD), acquiring 53,952 shares valued at approximately $16.66 million. This move aligns with other institutional investors like Vanguard Group Inc., Geode Capital Management LLC, and Norges Bank, which have also increased or initiated stakes in the medical instruments supplier. Insulet reported an EPS beat and significant revenue growth, with analysts maintaining a "Moderate Buy" consensus and an average price target of $379.00.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $390 | $412 | -5% |
| 2025-12-17 | Canaccord Genui | $450 | $432 | +4% |
| 2025-12-16 | Evercore ISI Gr | $370 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-16 | Evercore ISI Gr | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.30M) |
| Sells | 1 ($0.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 55.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+1.0%)
- FMR, LLC: 10.8% (+0.8%)
- Blackrock Inc.: 9.4% (+2.8%)
- Capital Research Glo: 6.5% (-4.0%)
- State Street Corpora: 4.4% (+1.1%)

### Key Risks

1. Premium valuation (P/E 46x, PEG 2.1x) vulnerable to multiple compression.
2. Long-term trend broken: trading 6.5% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.12 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (2.9x). Revenue growth strong at 21% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.0B |
| Beta | 1.40 |
| 52W Range | $230.05 - $354.88 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.12 |
| Forward P/E | 45.8 |
| Current P/E | 58.0 |
| YoY Growth | 26.4% |
| EPS Direction | RISING |

### Technicals

MRS_10 stable at -1.1% (minimal 5-day change). Below STRENGTH zone by 4.1pp (needs >3.0% for momentum thesis). Below SMA200 (0.94x), long-term trend not supportive. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.06% (CS: 24) | Neutral |
| RSI_14 | 35.3 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 0.976x | Below |
| vs SMA50 | 0.914x | Below |
| vs SMA200 | 0.935x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $283.51
- **Stop Loss:** $268.47 (5.3% risk)
- **Target:** $298.55 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 57
- **Position Value:** $16,160.07
- **Portfolio %:** 16.16%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-19 (Est: $1.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.15 | $1.24 | +8.1% |
| 2025Q2 | $0.92 | $1.17 | +26.8% |
| 2025Q1 | $0.79 | $1.02 | +29.7% |
| 2024Q4 | $1.02 | $1.15 | +12.6% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*